Revolution Medicines (RVMD) Current Assets (2019 - 2026)

Revolution Medicines' Current Assets history runs 8 years deep, the most recent figure standing at $2.0 billion for Q1 2026.

• On a quarterly basis, Current Assets fell 7.81% year-over-year to $2.0 billion in Q1 2026; TTM through Mar 2026 was $2.0 billion, a 7.81% decrease from a year earlier, with the FY2025 full-year figure at $2.1 billion, down 10.85% from the prior year.
• Current Assets declined to $2.0 billion in Q1 2026 per RVMD's latest filing, from $2.1 billion in the prior quarter.
• Across five years, Current Assets topped out at $2.3 billion in Q4 2024 and bottomed at $483.0 million in Q2 2022.
• The 5-year median for Current Assets is $1.6 billion (2024), against an average of $1.4 billion.
• Across the five-year window, Current Assets retreated 26.92% in 2022 and soared 184.66% in 2023, its largest moves.
• Year by year, Current Assets stood at $660.2 million in 2022, then surged by 184.66% to $1.9 billion in 2023, then advanced by 23.86% to $2.3 billion in 2024, then declined by 10.85% to $2.1 billion in 2025, then retreated by 5.16% to $2.0 billion in 2026.
• Per Business Quant, the three latest RVMD Current Assets figures stand at $2.0 billion (Q1 2026), $2.1 billion (Q4 2025), and $2.0 billion (Q3 2025).